Stock Alert: Novavax Up 50% On Positive Result For COVID Vaccine Candidate

Novavax, Inc. (NVAX) shares are spiking on Friday morning trade as the biotechnology company announced that its protein-based COVID-19 vaccine candidate NVX-CoV2372 met the primary endpoint in its Phase 3 in the U.K., with a vaccine efficacy of 89.3 percent. Novavax also announced successful results of its Phase 2b study in South Africa.